Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study
Open Access
- 14 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pulmonary Medicine
- Vol. 20 (1), 1-13
- https://doi.org/10.1186/s12890-020-01209-4
Abstract
In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. Due to a lack of clinical evidence and expertise, managing these AEs can be challenging for patients and physicians alike. In the absence of evidence, consensus recommendations from physicians experienced in using pirfenidone to treat IPF are beneficial. Using a modified Delphi process, expert recommendations were developed by a panel of physicians experienced with using pirfenidone for IPF. Over three iterations, panelists developed and refined a series of statements on the use of pirfenidone in IPF. Their agreement on each statement was ranked using a Likert scale. A panel of 12 physicians participated and developed a total of 286 statements on dosing and administration, special populations, drug-drug interactions, laboratory analysis, warnings and precautions, and AE management. Expert recommendations were achieved with regard to slower initial titrations and slower titrations for AEs, dosing with meal(s) or substantial meals, and adding other prescribed pharmacological agents for AEs. Until there is further clinical evidence, the resulting consensus recommendations are intended to provide direction on the practical management of IPF with pirfenidone, by encompassing a broad experience from the real world to complement data gleaned from clinical trials.Keywords
Funding Information
- Genentech
This publication has 28 references indexed in Scilit:
- A Delphi survey to determine how educational interventions for evidence-based practice should be reported: Stage 2 of the development of a reporting guidelineBMC Medical Education, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- Framework of behavioral indicators for outcome evaluation of TB health promotion: a Delphi study of TB suspects and Tb patientsBMC Infectious Diseases, 2014
- Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse EventsAdvances in Therapy, 2014
- Epidemiology of idiopathic pulmonary fibrosisClinical Epidemiology, 2013
- Protocol for development of the guideline for reporting evidence based practice educational interventions and teaching (GREET) statementBMC Medical Education, 2013
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus studyRespiratory Medicine, 2010
- The Delphi method and health researchHealth Education, 2003
- GROUP TECHNIQUES FOR PROGRAM PLANNING: A GUIDE TO NOMINAL GROUP AND DELPHI PROCESSES Andre L. Delbecq, Andrew H. Van de Ven, and David H. Gustafson Glenview, III.: Scott, Foresman, 1975. xv plus 174 pp., $4.95, paperbound. INTERPERSONAL CONFLICT RESOLUTION Alan C. Filley Glenview, III.: Scott, Foresman, 1975. 180 pp., $4.95, paperboundGroup & Organization Studies, 1976